Abstract
This case report describes the clinical course of a patient with progressing metastatic melanoma (M1a) under standard chemotherapy, followed by long-term partial remission of disease under treatment with experimental, specific immunotherapy. Detectable specific immune responses demonstrate the correlation between continued tumor regression and the administered specific immunotherapy.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Antigens, Neoplasm / immunology*
-
Antineoplastic Combined Chemotherapy Protocols
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / drug effects
-
CD8-Positive T-Lymphocytes / immunology
-
Cancer Vaccines / therapeutic use*
-
Chemotherapy, Adjuvant
-
Disease Progression
-
Epitopes / immunology*
-
Female
-
Follow-Up Studies
-
Humans
-
Hypersensitivity, Delayed / immunology
-
Immunotherapy / methods*
-
Injections, Intradermal
-
Leg*
-
Lymphatic Metastasis / pathology
-
Melanoma / drug therapy*
-
Melanoma / immunology
-
Melanoma / pathology
-
Melanoma / surgery
-
Melanoma-Specific Antigens
-
Middle Aged
-
Neoplasm Proteins / immunology*
-
Neoplasm Staging
-
Palliative Care
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / immunology
-
Skin Neoplasms / pathology
-
Skin Neoplasms / surgery
-
Survivors*
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
Epitopes
-
Melanoma-Specific Antigens
-
Neoplasm Proteins